275 related articles for article (PubMed ID: 38203436)
1. Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host's Immunity.
Mondelli MU; Ottolini S; Oliviero B; Mantovani S; Cerino A; Mele D; Varchetta S
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203436
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection.
Casey JL; Dore GJ; Grebely J; Matthews GV; Cherepanov V; Martinello M; Marks P; Janssen HLA; Hansen BE; Kaul R; MacParland SA; Gehring AJ; Feld JJ
J Viral Hepat; 2023 Jan; 30(1):64-72. PubMed ID: 36302162
[TBL] [Abstract][Full Text] [Related]
3. Innate and adaptive immune responses in HCV infections.
Heim MH; Thimme R
J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
[TBL] [Abstract][Full Text] [Related]
4. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.
Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H
J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532
[TBL] [Abstract][Full Text] [Related]
5. Increased peripheral CD4
Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
[TBL] [Abstract][Full Text] [Related]
6. Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection.
Casey JL; Feld JJ; MacParland SA
Cells; 2019 Apr; 8(4):. PubMed ID: 30959825
[TBL] [Abstract][Full Text] [Related]
7. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
Bukh J
J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
[TBL] [Abstract][Full Text] [Related]
8. Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
Hlady RA; Zhao X; El Khoury LY; Luna A; Pham K; Wu Q; Lee JH; Pyrsopoulos NT; Liu C; Robertson KD
Hepatology; 2022 Apr; 75(4):983-996. PubMed ID: 34387871
[TBL] [Abstract][Full Text] [Related]
9. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Martin B; Hennecke N; Lohmann V; Kayser A; Neumann-Haefelin C; Kukolj G; Böcher WO; Thimme R
J Hepatol; 2014 Sep; 61(3):538-43. PubMed ID: 24905492
[TBL] [Abstract][Full Text] [Related]
10. Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
Sasaki R; Meyer K; Moriyama M; Kato N; Yokosuka O; Ray RB; Aurora R; Ray R; Kanda T
J Med Virol; 2019 Mar; 91(3):411-418. PubMed ID: 30192392
[TBL] [Abstract][Full Text] [Related]
11. Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.
Cui A; Li B; Wallace MS; Gonye ALK; Oetheimer C; Patel H; Tonnerre P; Holmes JA; Lieb D; Yao BS; Ma A; Roberts K; Damasio M; Chen JH; Piou D; Carlton-Smith C; Brown J; Mylvaganam R; Hon Fung JM; Sade-Feldman M; Aneja J; Gustafson J; Epstein ET; Salloum S; Brisac C; Thabet A; Kim AY; Lauer GM; Hacohen N; Chung RT; Alatrakchi N
J Hepatol; 2024 Feb; 80(2):251-267. PubMed ID: 36972796
[TBL] [Abstract][Full Text] [Related]
12. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
[TBL] [Abstract][Full Text] [Related]
13. Pushing to a cure by harnessing innate immunity against hepatitis C virus.
Ireton RC; Gale M
Antiviral Res; 2014 Aug; 108():156-64. PubMed ID: 24907428
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma: biologic functions and HCV terapy (type I/II) (2 of 2 parts).
Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R
Clin Ter; 2006; 157(5):457-68. PubMed ID: 17147054
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
[TBL] [Abstract][Full Text] [Related]
16. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses.
Agrawal B; Kumar R
World J Gastroenterol; 2016 Jul; 22(25):5623-6. PubMed ID: 27433078
[TBL] [Abstract][Full Text] [Related]
17. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
Callendret B; Eccleston HB; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
Hepatology; 2016 May; 63(5):1442-54. PubMed ID: 26513111
[TBL] [Abstract][Full Text] [Related]
18. Immunological scars after cure of hepatitis C virus infection: Long-HepC?
Cornberg M; Mischke J; Kraft AR; Wedemeyer H
Curr Opin Immunol; 2023 Jun; 82():102324. PubMed ID: 37043890
[TBL] [Abstract][Full Text] [Related]
19. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
Hartlage AS; Walker CM; Kapoor A
J Virol; 2020 May; 94(10):. PubMed ID: 32102885
[TBL] [Abstract][Full Text] [Related]
20. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
Gobran ST; Pagliuzza A; Khedr O; Fert A; Chomont N; Bruneau J; Klein MB; Ancuta P; Shoukry NH
J Virol; 2023 Dec; 97(12):e0110523. PubMed ID: 38051044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
